Open: 1.05 Close: 1.04 Change: -0.01

Today's Summary

Cocrystal Pharma ( (COCP) has issued an announcement on January 9, 2026. Compensation Committee approved grants of non-qualified stock options. Cocrystal plans to initiate a human norovirus challenge study in 2025 for the treatment and prevention of norov virus infection. CDI-988 has potential to be a first-in-class oral antiviral treatment for Norovirus and other viral infections. De-industrialisation need not be synonymous with decay, says David Autor and Gordon Hanson, who coined the term ‘China Shock’ in the 2000s. China is aggressively contesting the innovative sectors where the United States has long been the leader.